MK-5909-003 R-DXd in People With OC

Who Can Participate in the Study?

Age Group
Adults

Study Details

Full Title
A Phase 1b/2 Open-label, Multicenter Study to Evaluate the Safety and Efficacy of Raludotatug Deruxtecan With or Without Other Anticancer Investigational Agents in Participants With High-grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Have Relapsed After Prior Platinum-based Chemotherapy
Principal Investigator
Professor of Obstetrics and Gynecology
Protocol Number
IRB: PRO00119750
NCT: NCT06843447
Phase
Phase I/II
ClinicalTrials.gov
Status
OPEN TO ACCRUAL
Participate